Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year?

Group 1 - Amylyx Pharmaceuticals, Inc. (AMLX) is currently outperforming its peers in the Medical sector, with a year-to-date gain of approximately 278.6% compared to the sector average of 2.1% [4] - The Zacks Rank for AMLX is 2 (Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for AMLX's full-year earnings has increased by 6.9% over the past quarter, reflecting stronger analyst sentiment [4] Group 2 - Amylyx Pharmaceuticals, Inc. is part of the Medical - Drugs industry, which consists of 146 stocks and is currently ranked 66 in the Zacks Industry Rank [6] - The Medical - Drugs industry has seen an average gain of 7.5% year-to-date, indicating that AMLX is performing better than its industry peers [6] - Another notable stock in the Medical sector is Aveanna Healthcare (AVAH), which has returned 99.6% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5][7]